Heron Stock Today

HRTX -  USA Stock  

USD 10.30  0.24  2.28%

Heron Therapeutics is trading at 10.30 as of the 25th of October 2021; that is -2.28 percent decrease since the beginning of the trading day. The stock's open price was 10.54. Heron Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Heron Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of July 2021 and ending today, the 25th of October 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 90
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 101.83 M outstanding shares of which 26.37 M shares are currently shorted by private and institutional investors with about 24.5 trading days to cover. More on Heron Therapeutics

Heron Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Heron Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Heron Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Heron Therapeutics generated a negative expected return over the last 90 days
Heron Therapeutics has a very high chance of going through financial distress in the upcoming years
Heron Therapeutics was previously known as Heron Therapeutics and was traded on NASDAQ Exchange under the symbol APPA.
The company reported the previous year's revenue of 83.03 M. Net Loss for the year was (234.14 M) with loss before overhead, payroll, taxes, and interest of (120.88 M).
Heron Therapeutics currently holds about 257.68 M in cash with (199.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.53.
Heron Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from www.equities.com: Heron falls 1.26 percent for October 20 - Equities.com
Heron Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Heron Therapeutics SEC Filings
Heron Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameHeron Therapeutics
Older SymbolAPPA
CEO, DirectorBarry Quart  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Cancer Fighters
Average Analyst Recommendation
Analysts covering Heron Therapeutics report their recommendations after researching Heron Therapeutics' financial statements, talking to executives and customers, or listening in on Heron Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Heron Therapeutics. The Heron consensus assessment is calculated by taking the average forecast from all of the analysts covering Heron Therapeutics.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Heron Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Heron Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares97.9 M90.8 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted97.9 M90.8 M
Significantly Up
Increasing
Slightly volatile
Total Assets291.3 M353.6 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities126.3 M117.1 M
Significantly Up
Increasing
Slightly volatile
Current Assets264.7 M314.2 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities110.6 M102.5 M
Significantly Up
Increasing
Slightly volatile
Total Debt20.8 M24.6 M
Fairly Down
Increasing
Slightly volatile
Gross Margin0.650.592
Significantly Up
Decreasing
Slightly volatile
Asset Turnover0.210.214
Fairly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Heron Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Heron Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Heron Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Heron Therapeutics' financial leverage. It provides some insight into what part of Heron Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Heron Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Heron Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Heron Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 165.16 M in liabilities with Debt to Equity (D/E) ratio of 1.03, which is about average as compared to similar companies. Heron Therapeutics has a current ratio of 4.38, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(189.68 Million)Share
Heron Therapeutics (HRTX) is traded on NASDAQ Exchange in USA. It is located in 4242 Campus Point Court Suite 200, San Diego, CA 92121, United States and employs 223 people. Heron Therapeutics was previously known as Heron Therapeutics and was traded on NASDAQ Exchange under the symbol APPA. Heron Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Heron Therapeutics's market, we take the total number of its shares issued and multiply it by Heron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Heron Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 101.83 M outstanding shares of which 26.37 M shares are currently shorted by private and institutional investors with about 24.5 trading days to cover. Heron Therapeutics currently holds about 257.68 M in cash with (199.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.53.
Check Heron Therapeutics Probability Of Bankruptcy
Ownership
Heron Therapeutics has a total of one hundred one million eight hundred thirty thousand outstanding shares. The majority of Heron Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Heron Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Heron Therapeutics. Please pay attention to any change in the institutional holdings of Heron Therapeutics as this could imply that something significant has changed or about to change at the company. Also note that almost five million ninety-one thousand five hundred invesors are currently shorting Heron Therapeutics expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Heron Ownership Details

Heron Stock Price Odds Analysis

What are Heron Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Heron Therapeutics jumping above the current price in 90 days from now is about 92.03%. The Heron Therapeutics probability density function shows the probability of Heron Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Heron Therapeutics has a beta of 0.6537. This usually indicates as returns on the market go up, Heron Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Heron Therapeutics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Heron Therapeutics is significantly underperforming DOW.
 Odds Down 10.3HorizonTargetOdds Up 10.3 
7.90%90 days
 10.30 
92.03%
Based on a normal probability distribution, the odds of Heron Therapeutics to move above the current price in 90 days from now is about 92.03 (This Heron Therapeutics probability density function shows the probability of Heron Stock to fall within a particular range of prices over 90 days) .

Heron Therapeutics Historical Income Statement

Heron Therapeutics Income Statement is one of the three primary financial statements used for reporting Heron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Heron Therapeutics revenue and expense. Heron Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Heron Therapeutics Weighted Average Shares is fairly stable at the moment as compared to the past year. Heron Therapeutics reported Weighted Average Shares of 90.77 Million in 2020. Weighted Average Shares Diluted is likely to rise to about 97.9 M in 2021, whereas Direct Expenses is likely to drop slightly above 30 M in 2021. View More Fundamentals

Heron Stock Against Markets

Picking the right benchmark for Heron Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Heron Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Heron Therapeutics is critical whether you are bullish or bearish towards Heron Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Heron Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Heron Therapeutics Corporate Directors

Heron Therapeutics corporate directors refer to members of a Heron Therapeutics board of directors. The board of directors generally takes responsibility for the Heron Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Heron Therapeutics' board members must vote for the resolution. The Heron Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Stephen Davis - DirectorProfile
Kimberly Manhard - Independent DirectorProfile
Christian Waage - DirectorProfile
John Poyhonen - Independent DirectorProfile
Please check Risk vs Return Analysis. Note that the Heron Therapeutics information on this page should be used as a complementary analysis to other Heron Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Heron Stock analysis

When running Heron Therapeutics price analysis, check to measure Heron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeutics is operating at the current time. Most of Heron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Heron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heron Therapeutics' price. Additionally, you may evaluate how the addition of Heron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Heron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeutics. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heron Therapeutics is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeutics' market value can be influenced by many factors that don't directly affect Heron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.